The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
The following are today's upgrades for Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.
The following are today's upgrades for Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.
The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
The following are today's upgrades for Validea's Patient Investor model based on the published strategy of Warren Buffett. This strategy seeks out firms with long-term, predictable profitability and low debt that trade at reasonable valuations.
Vir Biotechnology (NASDAQ: VIR) may not be a familiar name to many investors. This relatively young biotech went public last October. Backed by infamous investor SoftBank (of WeWork fame) among others, investors in Vir find themselves in a situation where they truly are betting
I'm a big believer in "skin in the game." If someone -- like me -- is going to write about how a stock is a great buy, I think they'd better back that up with their own money. Otherwise, if the stock tanks, the writer still gets paid while everyone who took that advice loses mon
U.S. Air Force brass have been attempting for years to ground the service's fleet of A-10 "Warthog" ground-attack jet fighters. Now they're at it again -- but this time there's a novel twist to this story. At the same time as one arm of the Pentagon works to cancel the A-10, a
Shareholders of Micron Technology (NASDAQ: MU) are used to volatility. After rising almost 500% from 2016 to mid-2018, shares dropped around 50% for the rest of the year as semiconductor prices fell from oversupply. Then shares rose more than 60% in 2019, and now sit even with h
It is difficult to ignore an eye-popping 7%-plus yield from a 110-year-old company with operations across 78 countries. BP (NYSE: BP) posted pretty good fourth-quarter results, considering the current energy market environment. What's more, it looks set for growth in the years t
Tandem Diabetes Care (NASDAQ: TNDM) owned less than 5% of the insulin pump market in the U.S. five years ago. The market has grown 40% since then, but the company now has 20% market share. It's not an overnight success, but it's close.
There are a lot of promising stocks out there for investors to choose from. However, if you're looking for companies with the most growth potential, the world of small-cap stocks is one of the best places to look.
Finances can be a major stressor for many households. In fact, money is the number one source of stress among Americans, according to a survey from Northwestern Mutual, with roughly half of workers saying they feel anxious, fearful, or insecure about their finances often or all